Morpholino

MO1-npl

ID

ZDB-MRPHLNO-190828-2

Name

MO1-npl

Previous Names

npl-atg (1)

Target

npl (1)

Sequence

5' - CGCGTTGAGACATTTCTTCCTTTCA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-npl

No data available

Phenotype

Phenotype resulting from MO1-npl

Phenotype	Fish	Figures
caudal fin curved, abnormal	WT + MO1-npl	Fig. 4 from Wen et al., 2018
extraocular musculature absent, abnormal	WT + MO1-npl	Fig. S4 from Wen et al., 2018
head muscle absent, abnormal	WT + MO1-npl	Fig. S4 from Wen et al., 2018
heart looping decreased occurrence, abnormal	twu34Tg + MO1-npl	Fig. 4, Fig. 9 from Wen et al., 2018
locomotory behavior decreased process quality, abnormal	WT + MO1-npl	Fig. 5 from Wen et al., 2018
muscle disorganized, abnormal	WT + MO1-npl	Fig. 8 from Wen et al., 2018
muscle cell disorganized, abnormal	WT + MO1-npl	Fig. 4, Fig. 9 from Wen et al., 2018
pericardium edematous, abnormal	WT + MO1-npl	Fig. 4 from Wen et al., 2018
skeletal muscle morphology, abnormal	WT + MO1-npl	Fig. S4 from Wen et al., 2018
skeletal muscle reactive oxygen species increased amount, abnormal	WT + MO1-npl	Fig. 5 from Wen et al., 2018
somite disorganized, abnormal	WT + MO1-npl	Fig. 4 from Wen et al., 2018

Phenotype of all Fish created by or utilizing MO1-npl

Phenotype	Fish	Conditions	Figures
muscle disorganized, abnormal	WT + MO1-npl	control	Fig. 8 from Wen et al., 2018
skeletal muscle reactive oxygen species increased amount, abnormal	WT + MO1-npl	standard conditions	Fig. 5 from Wen et al., 2018
skeletal muscle reactive oxygen species amount, ameliorated	WT + MO1-npl	chemical treatment by environment: N-acetylmannosamine	Fig. 5 from Wen et al., 2018
muscle cell organized, ameliorated	WT + MO1-npl	chemical treatment by environment: N-acetyl-D-glucosamine	Fig. 9 from Wen et al., 2018
pericardium edematous, abnormal	WT + MO1-npl	standard conditions	Fig. 4 from Wen et al., 2018
somite disorganized, abnormal	WT + MO1-npl	standard conditions	Fig. 4 from Wen et al., 2018
muscle cell organized, ameliorated	WT + MO1-npl	chemical treatment by environment: sialic acid	Fig. 9 from Wen et al., 2018
locomotory behavior decreased process quality, abnormal	WT + MO1-npl	standard conditions	Fig. 5 from Wen et al., 2018
muscle disorganized, abnormal	WT + MO1-npl	chemical treatment by environment: D-galactose	Fig. 8 from Wen et al., 2018
muscle organized, ameliorated	WT + MO1-npl	chemical treatment by environment: N-acetylmannosamine	Fig. 8 from Wen et al., 2018
head muscle absent, abnormal	WT + MO1-npl	standard conditions	Fig. S4 from Wen et al., 2018
caudal fin curved, abnormal	WT + MO1-npl	standard conditions	Fig. 4 from Wen et al., 2018
extraocular musculature absent, abnormal	WT + MO1-npl	standard conditions	Fig. S4 from Wen et al., 2018
locomotory behavior process quality, ameliorated	WT + MO1-npl	chemical treatment by environment: N-acetylmannosamine	Fig. 5 from Wen et al., 2018
muscle disorganized, abnormal	WT + MO1-npl	chemical treatment by environment: D-mannose	Fig. 8 from Wen et al., 2018
muscle cell disorganized, abnormal	WT + MO1-npl	standard conditions	Fig. 4, Fig. 9 from Wen et al., 2018
muscle organized, ameliorated	WT + MO1-npl	chemical treatment by environment: sialic acid	Fig. 8 from Wen et al., 2018
muscle organized, ameliorated	WT + MO1-npl	chemical treatment by environment: N-acetyl-D-glucosamine	Fig. 8 from Wen et al., 2018
muscle disorganized, abnormal	WT + MO1-npl	chemical treatment by environment: D-xylose	Fig. 8 from Wen et al., 2018
muscle cell organized, ameliorated	WT + MO1-npl	chemical treatment by environment: N-acetylmannosamine	Fig. 9 from Wen et al., 2018
skeletal muscle morphology, abnormal	WT + MO1-npl	standard conditions	Fig. S4 from Wen et al., 2018
heart looping decreased occurrence, abnormal	twu34Tg + MO1-npl	chemical treatment by environment: sialic acid	Fig. 9 from Wen et al., 2018
heart looping occurrence, ameliorated	twu34Tg + MO1-npl	chemical treatment by environment: N-acetylmannosamine	Fig. 9 from Wen et al., 2018
heart looping decreased occurrence, abnormal	twu34Tg + MO1-npl	control	Fig. 4, Fig. 9 from Wen et al., 2018
heart looping decreased occurrence, abnormal	twu34Tg + MO1-npl	chemical treatment by environment: N-acetyl-D-glucosamine	Fig. 9 from Wen et al., 2018

Citations